Welcome to the international HTA database

Showing [21959 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Neurophysiological facial nerve monitoring during parotid gland surgery]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Polatuzumab vedotin (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[PSMA PET/CT staging in patients with prostate cancer biochemical recurrence]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: high-dose vitamin C injections for cancer patients in Quebec]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tisagenlecleucel (follicular lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Lutetium 177 PSMA in patients with prostate cancer]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Enfortumab vedotin (urothelial cancer) - Benefit assessment according to §35a Social Code Book V]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Elexacaftor/tezacaftor/ivacaftor in cystic fibrosis]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Setmelanotide (obesity and control of hunger in POMC, PCSK1 or LEPR deficiency obesity) - Assessment according to §35a (para. 1, sentence 11) Social Code Book VAuftraggeber: G-BA]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Gated-SPECT in ischemic non-obstructive coronary artery disease (microvascular angina - INOCA)]
2022	Ontario Health	Molecular testing for thyroid nodules with atypical cells of indeterminate significance
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Vagus nerve stimulation for drug-resistant epilepsy]
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Adalimumab for the treatment of adults with non-infectious uveitis
2022	Ontario Health	Genetic testing for familial hypercholesterolemia
2022	NIHR Health Technology Assessment programme	Outcome after selective early closure of ductus arteriosus in extremely preterm babies (Baby-OSCAR trial)
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[308nm excimer laser or 308nm excimer light in patients with vitiligo]
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Adalimumab for the treatment of pediatric populations with non-infectious uveitis
2022	Ontario Health	Pre-surgical nasal decolonization of staphylococcus aureus
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Sialendoscopy for obstructive salivary gland disease]
2022	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Treatments for extreme nausea and vomiting in pregnancy (hyperemesis gravidarum)]
2022	Austrian Institute for Health Technology Assessment (AIHTA)	Wearable cardioverter-defibrillator (WCD) therapy for primary and secondary prevention of sudden cardiac arrest. Update 2022
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Fecal microbiota transplantation for recurrent Clostridioides difficile infection]
2022	Austrian Institute for Health Technology Assessment (AIHTA)	Long COVID care pathways and structures: an updated scoping review
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Casirivimab and imdevimab to treat Covid-19 in patients negative for the Omicron genotype]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Onasemnogene abeparvovec (Zolgensma®) for spinal muscular atrophy]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Radiofrequency-assisted surgery in inferior turbinate hypertrophy]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Fluorodopa PET scanning in Parkinson’s disease]
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Stakeholders' perspectives of mobile x-ray services in support of healthcare-in-place in residential aged care facilities: a qualitative study
2022	NIHR Health Technology Assessment programme	Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Corneal collagen crosslinking with riboflavin in keratoconus]
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Residents' perspectives of mobile X-ray services in support of healthcare-in-place in residential aged care facilities: a qualitative study.
2022	NIHR Health Services and Delivery Research programme	Perioperative exercise programmes to promote physical activity in the medium to long term: systematic review and qualitative research
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Adjunctive colposcopy technologies (videocolposcopy) for cervical conditions]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: risks of hospitalization and death related to COVID-19 in people with physical disabilities using rehabilitation services]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Prenatal cell-free DNA in maternal blood screening to assess chromosomal disorders in single pregnancy]
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	The utilization and national variation of plain x-ray services by Australian residents of long-term care facilities
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: risks of hospitalization and death related to COVID-19 in people with intellectual disabilities (ID) or autism spectrum disorder (ASD)]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Antiangiogenic drugs in refractory age-related macular degeneration]
2022	NIHR Health Technology Assessment programme	A randomised controlled trial of a protease inhibitor monotherapy versus continuing combination antiretroviral therapy for HIV-1 infected patients previously established on a dual nucleoside and non-nucleoside combination regimen
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: use of microsurgery for the prevention and treatment of cancer-related lymphedema]
2022	Andalusian Health Technology Assessment Area (AETSA)	[Clinical effectiveness, safety, and economic assessment of mass screening for hepatitis C. Systematic review]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Bariatric surgery in obese patients with gastroesophageal reflux and/or Barrett’s esophagus]
2023	WorkSafeBC	Cold plunges as treatment for concussions
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: Optune - for the treatment of adult patients with newly diagnosed glioblastoma]
2023	NIHR Health Services and Delivery Research programme	Impact of interventions to improve recovery of older adults following planned hospital admission on quality-of-life following discharge: linked-evidence synthesis
2023	NIHR Health Services and Delivery Research programme	The effectiveness and acceptability of multimedia information when recruiting children and young people to trials: the TRECA meta-analysis of SWATs
2023	NIHR Health Technology Assessment programme	The potential impact of policies and structural interventions in reducing cardiovascular disease and mortality: a systematic review of simulation-based studies
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Dental bridges for partial tooth loss
2023	NIHR Health Services and Delivery Research programme	Evaluating mental health decision units in acute care pathways (DECISION): a quasi-experimental, qualitative and health economic evaluation
2023	Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	Evondos® medicine-dispensing service
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Treatment of adult patients with chronic immune thrombocytopenia after failure of first-line therapies
2023	NIHR Health Technology Assessment programme	Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis
2023	Ontario Health	Bariatric surgery for people with class I obesity and poorly controlled type 2 diabetes
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Rapid response: Cervical cancer: transition from from Pap test screening to HPV testing]
2023	NIHR Health Technology Assessment programme	Treatment of Hidradenitis Suppurativa Evaluation Study: the THESEUS prospective cohort study
2023	Ontario Health	Testing for homologous recombination deficiency in patients diagnosed with ovarian cancer
2023	Institute for Clinical and Economic Review (ICER)	Fezolinetant for moderate to severe vasomotor symptoms associated with menopause: effectiveness and value
2023	NIHR Health Technology Assessment programme	Techniques to increase lumbar puncture success in newborn babies: the NeoCLEAR RCT
2023	Ontario Health	Wire-free, nonradioactive localization techniques to guide surgical excision of nonpalpable breast cancer tumours
2023	Ontario Health	Placental growth factor (PlGF)-based biomarkers for risk prediction in people with suspected preeclampsia
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Image-guided spinal injections in the treatment of chronic spinal pain: an overview of evidence-based guideline recommendations and specific focus on guidance techniques
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Robot-assisted rehabilitation for incomplete spinal cord injury]
2023	Institute for Clinical and Economic Review (ICER)	Gene therapies for sickle cell disease: effectiveness and value
2023	Austrian Institute for Health Technology Assessment (AIHTA)	SMA therapies: mid- to long-term follow-up of spinal muscular atrophy (SMA) patients treated for ≥24 months with nusinersen or onasemnogene abeparvovec and ≥12 months for patients treated with risdiplam or combination therapies
2023	Institute for Clinical and Economic Review (ICER)	Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH)
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Strategies for recruitment and programme adherence in group programmes for children, adolescents and adults with overweight and grade 1 obesity]
2023	Institute for Clinical and Economic Review (ICER)	Lecanemab for early Alzheimer’s disease
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Myopia control spectacle lenses for children and adolescents]
2023	Institute for Clinical and Economic Review (ICER)	Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Registries in Austria and their utilisation for healthcare improvement]
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Autologous fat grafting in osteoarthritis]
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Endovenous laser therapy for varicose veins in the lower extremities]
2023	NIHR Health Technology Assessment programme	Views of female genital mutilation survivors, men and health-care professionals on timing of deinfibulation surgery and NHS service provision: qualitative FGM Sister Study
2023	Institute for Clinical and Economic Review (ICER)	Value assessment framework
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fibromatoses of the hand (Dupuytren's disease) and / or foot (Ledderhose's disease): do those affected benefit from radiation therapy?]
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Effectiveness and safety of coronary sinus narrowing device for the treatment of refractory angina]
2023	Institute for Clinical and Economic Review (ICER)	ICER-PHTI assessment framework for digital health technologies
2023	Institute for Clinical and Economic Review (ICER)	White bagging, brown bagging, and site of service policies: best practices in addressing provider markup in the commercial insurance market
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Restless legs syndrome: can the symptoms be alleviated through non-medicinal procedures?]
2023	Institute for Clinical and Economic Review (ICER)	Applying the results of comparative effectiveness research to control drug costs: policy options for California
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Contraception: comparison of hormonal coils and copper coils]
2023	Norwegian Institute of Public Health (NIPH)	177Lu-PSMA-617 for treatment of metastatic castration resistant prostate cancer: a health technology assessment
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Evaluation of the lung cancer screening program]
2023	Institute for Clinical and Economic Review (ICER)	Advancing health technology assessment methods that support health equity
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Ovarian tissue cryopreservation and transplantation in patients with cancer or benign diseases to fertility preservation]
2023	Institute for Clinical and Economic Review (ICER)	Assessment of barriers to fair access
2023	National Evidence-based Healthcare Collaborating Agency (NECA)	[Low-level light therapy for primary dysmenorrhea]
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Efficacy and safety of Emotional Freedom Techniques for the treatment of anxiety, depression and post traumatic stress disorders]
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Effectiveness of communication strategies for patients who are non-vocal due to artificial airways
2023	Health Technology Wales (HTW)	Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Invasive monitoring of pulmonary artery pressure in patients with symptomatic heart failure]
2023	Health Information and Quality Authority (HIQA)	Rapid health technology assessment of continuous glucose monitoring in adults with type 1 diabetes mellitus
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Robotic surgery in benign and malignant surgical pathology (urology, general and digestive surgery, cardiothoracic surgery, gynecology, endocrinology, ophthalmology, and head and neck surgery). Chapter I: cardiothoracic, endocrine, ophthalmological surgery, and head and neck surgery]
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Early detection tools for emotional distress in adult people with cancer]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Robotic surgery in benign and malignant surgical pathology (urology, general and digestive surgery, cardiothoracic surgery, gynecology, endocrinology, ophthalmology, and head and neck surgery). Chapter II: urological, gynecological, general and digestive surgery]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Spinal cord stimulation in refractory neuropathic pain in adults: evaluation of efficacy, effectiveness, safety, and efficiency in painful diabetic neuropathy and failed back surgery and complex regional pain syndromes]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evaluation of the safety, diagnostic validity, and clinical effectiveness of transcutaneous measurement of partial pressure of oxygen in the management of diabetic foot]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evaluation of early intervention programs in psychosis for adolescents and young adults]
2023	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	Assessment of hip protectors for users at risk of falls
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Artificial intelligence for the detection of colorectal precancerous lesions in colonoscopy]